Condition
Gastroesophageal Junction Adenocarcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 34 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
34 shownA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499 · 2025-08-20
RECRUITINGBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadNCT06324357 · 2024-06-28
RECRUITINGComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramNCT06265285 · 2024-04-30
RECRUITINGA Study of KK2269 in Adult Participants With Solid TumorsNCT06266299 · 2024-01-18
RECRUITINGA Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsNCT06131840 · 2023-11-20
RECRUITINGSafety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379 · 2023-11-01
RECRUITINGCollecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069 · 2022-08-18
RECRUITINGA Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632 · 2020-06-08
RECRUITINGA Multicenter Cancer Biospecimen Collection StudyNCT04510129 · 2020-02-05
RECRUITINGAPL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsNCT03175224 · 2017-09-27
RECRUITINGA Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid TumorsNCT07807956 · 2026-09-01
NOT_YET_RECRUITINGA Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06560645 · 2024-11-04
TERMINATEDPhase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201NCT06341647 · 2024-10-31
WITHDRAWNA Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsNCT06549816 · 2024-08-21
COMPLETEDA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsNCT06157892 · 2024-05-20
ACTIVE_NOT_RECRUITINGA Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsNCT05678205 · 2023-08-01
WITHDRAWNXNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.NCT06792435 · 2023-07-27
ACTIVE_NOT_RECRUITINGA Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesNCT04772989 · 2021-03-19
COMPLETEDSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNCT04140526 · 2020-09-16
ACTIVE_NOT_RECRUITINGPhase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsNCT04344795 · 2020-05-06
COMPLETEDPhase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)NCT04152499 · 2020-02-28
ACTIVE_NOT_RECRUITINGA Study of Ladiratuzumab Vedotin in Advanced Solid TumorsNCT04032704 · 2019-10-09
TERMINATEDGB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaNCT04060342 · 2019-08-13
TERMINATEDSL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasNCT03894618 · 2019-03-26
COMPLETEDA Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ AdenocarcinomaNCT03852251 · 2019-01-18
COMPLETEDA Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced CancerNCT03735290 · 2019-01-14
TERMINATEDPembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)NCT03615326 · 2018-10-05
COMPLETEDStudy of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960 · 2017-09-05
ACTIVE_NOT_RECRUITINGPEN-866 in Patients With Advanced Solid MalignanciesNCT03221400 · 2017-08-29
UNKNOWNA Safety Study of SGN-2FF for Patients With Advanced Solid TumorsNCT02952989 · 2017-02-23
TERMINATEDEfficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)NCT03019588 · 2017-02-16
TERMINATEDA Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesNCT02572687 · 2016-02-19
COMPLETEDA Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)NCT02335411 · 2015-02-03
COMPLETEDA Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced CancerNCT02082210 · 2014-03-07
COMPLETEDCommon interventions
pembrolizumabDRUG8CapecitabineDRUG4cisplatinDRUG3OxaliplatinDRUG3PembrolizumabBIOLOGICAL35-FUDRUG2AB-201DRUG2BevacizumabDRUG2CarboplatinDRUG2CyclophosphamideDRUG2DocetaxelDRUG2FludarabineDRUG2PaclitaxelDRUG2Questionnaire AdministrationOTHER2RamucirumabDRUG2sigvotatug vedotinDRUG25-Fluorouracil (5-FU)DRUG1AB308DRUG1ABBV-253DRUG1AK104BIOLOGICAL1APL-101 Oral CapsulesDRUG1atezolizumabDRUG1Biospecimen CollectionPROCEDURE1cabozantinibDRUG1CarboplatinCOMBINATION_PRODUCT1
Leading sponsors
Seagen, a wholly owned subsidiary of Pfizer
4
Merck Sharp & Dohme LLC
3
Eli Lilly and Company
2
Seagen Inc.
2
AbbVie
1
Akeso
1
Alliance for Clinical Trials in Oncology
1
Apollomics Inc.
1
Arcus Biosciences, Inc.
1
Artiva Biotherapeutics, Inc.
1
Astellas Pharma Global Development, Inc.
1
Boehringer Ingelheim
1
Cofactor Genomics, Inc.
1
Exelixis
1
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
1
Trial status mix
RECRUITING10
COMPLETED9
TERMINATED6
ACTIVE_NOT_RECRUITING5
WITHDRAWN2
NOT_YET_RECRUITING1
UNKNOWN1
Phase mix
PHASE125
PHASE214
PHASE32
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.